ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
|
|
- Eileen Bates
- 6 years ago
- Views:
Transcription
1 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation :
2 Introduction and Background Heart failure is a major public health problem, especially in persons 65 years of age and older (= number one reason for hospitalizations in this age group). Age-adjusted incidence per 100,000 personyears during was 564 for men and 327 for women, age years (NEJM, 2002, Framingham) Five-year age-adjusted survival rate was only 59% among men and 45% for women. In 91% of HF cases, hypertension is an antecedent (Framingham, JAMA, 1996) 2
3 3 ALLHAT Hypertension Control and Heart Failure In a meta-analysis of 12 trials of patients with hypertension it was found that, compared to placebo, drug therapy for hypertension prevents over 50% of HF events (Moser, JACC, 1996). In another meta-analysis, diuretics and betablockers (BB) were equally effective in preventing HF events (Psaty, JAMA, 1997).
4 4 ALLHAT Hypertension Control and Heart Failure A meta analysis of active comparator trials found no significant difference between ACEinhibitors and diuretics for preventing HF; ACEinhibitors were more efficacious than CCBs (BPLTT Collaboration, Lancet, 2002). The INSIGHT trial found that a long-acting nifedipine regimen was associated with a > 2x higher incidence of HF events compared to a diuretic combination (HCTZ/amiolride) (Brown, Lancet, 2000).
5 5 ALLHAT Objectives Characterize HF in ALLHAT by its antecedent risk factors and underlying conditions. Examine occurrence of HF by treatment group overall, in subgroups, and over time. Explore relation of initial occurrence of HF to pre-randomization type of BP medication used. Explore follow-up BP and use of additional drugs as mediating/modifying factors. Examine post-hf mortality overall and by treatment group.
6 Randomized Design of ALLHAT Hypertension Trial 6 42,418 high-risk hypertensive patients 90% previously treated 10% untreated STEP 1 AGENTS Chlorthalidone mg Amlodipine mg Lisinopril mg Doxazosin 1-8 mg N=15,255 N=9,048 N=9,054 N=9,061 Atenolol 28.0% STEP 2 AND 3 AGENTS (5 years) Clonidine 10.6% Reserpine 4.3% Hydralazine 10.9% Other AHT Drugs
7 7 ALLHAT Decision to Stop Doxazosin Arm NHLBI Director accepted recommendation of independent review group to terminate doxazosin arm (early in year 2000), due to: Futility of finding a significant difference for primary outcome Statistically significant 25 percent higher rate of major secondary endpoint, combined CVD outcomes, along with twofold higher rate of HF Detailed HF analyses published (Davis et al. Ann Intern Med 2002).
8 8 ALLHAT Heart Failure Data Collection Hospitalized nonfatal discharge summary Hospitalized fatal death certificate, discharge summary Nonhospitalized fatal death certificate Nonhospitalized nonfatal (treated) clinician report 100% review of discharge summaries and death certificates by CTC Medical Reviewers Queries to clinics if diagnosis questionable
9 9 ALLHAT Category A ALLHAT Criteria for HF Evaluation* Must have one from each category: Category B Paroxysmal nocturnal dyspnea Dyspnea at rest NYHA Classification III Orthopnea Rales 2+ ankle edema Tachycardia Cardiomegaly by CXR CXR characteristic of CHF S 3 gallop Jugular venous distention *ALLHAT Manual of Operations, 5.3.4; adopted from the SHEP trial
10 Validity of HF Outcome Verified 10 Traditional risk factors in agreement with previous studies, e.g., Framingham HF Validation Study confirmed original observed treatment differences Independent central review using both ALLHAT and Framingham criteria
11 Heart Failure Validation Study 11 Criteria % Agreement ALLHAT 71% Framingham Heart Study 80% Reviewers judgement 84%
12 12 Inclusion/Exclusion Criteria for Antihypertensive Trial Men and women > 55 years old If untreated: 140/90, 180/110 mm Hg (2 visits) If treated: 160/100 mm Hg (visit 1), 180/110 mm Hg (visit 2) No washout required At least one additional cardiovascular risk factor Exclude if symptomatic HF or EF < 35%, creatinine 2 mg/dl, require diuretics, CCB, ACEI, or AB s for non-bp indication
13 Step 1 Treatment Protocol 13 Step 1 Agent Initial Dose* Dose 1* Dose 2* Dose 3* Chlorthalidone Amlodipine Lisinopril Doxazosin * mg/day Step 2/3 drugs atenolol, reserpine, clonidine, hydralazine Non-study drugs all other antihypertensive medications
14 Baseline Characteristics Hospitalized/Fatal HF During Trial Yes No Difference p N 1,773 31,584 Age (mean) <0.001 Men, % 55.2% 53.0% +2.2% Pre-RZ Treatment, % 93.1% 90.0% +3.1% SBP (mean mm Hg) <0.001 DBP (mean mm Hg) <0.001 Pulse (mean bpm) <0.001 Cigarette smoking, % 18.3% 22.1% -3.8 <0.001 Diabetes, % % <0.001 LVH by ECG, % 18.4% 16.3% +2.1% <0.001 History of CHD, % 37.6% 24.7% <0.001 BMI (mean) <
15 Hospitalized/ Fatal Heart Failure by ALLHAT Treatment Group 15 Cumulative Event Rate RR 95% CI A-C L-C A-L Chlorthalidone Amlodipine Lisinopril Years
16 16 ALLHAT Heart Failure Before and After 1 Year Observed HF differences were larger earlier in the follow-up. The lisinopril group had a lower HF rate than the amlodipine group, but event curves did not separate until later. A test of the proportional hazards assumption for Cox regression revealed that RRs were not constant over time. Therefore, a Cox regression that used a time-dependent indicator variable (<=1 year versus >1 year) was utilized.
17 Hospitalized/ Fatal Heart Failure by ALLHAT Treatment Group Within 1 Year and >1 Year 17 Baseline to Year 1 > Year 1 RR 95% CI RR 95% CI A-C A-C L-C L-C Cumulative Hosp/Fatal HF Rate A-L Chlorthalidone Amlodipine Lisinopril A-L Years to Hosp/Fatal HF Years to Hosp/Fatal HF
18 Hospitalized/fatal HF in Subgroups - Amlodipine / Chlorthalidone Relative Risks from Baseline to 1 Year of Follow-up 18 Relative Risk (95% CI) Favors Amlodipine Favors Chlorthalidone Total Age < 65 Age 65 Non-Black Black Men Women Diabetic Non-Diabetic 2.22 ( ) 2.89 ( ) 2.06 ( ) 2.12 ( ) 2.37 ( ) 2.27 ( ) 2.17 ( ) 2.71 ( ) 1.83 ( )
19 Hospitalized/fatal HF in Subgroups - Amlodipine / Chlorthalidone Relative Risks After 1 Year of Follow-up 19 Relative Risk (95% CI) Favors Amlodipine Favors Chlorthalidone Total Age < 65 Age 65 Non-Black Black Men Women Diabetic Non-Diabetic 1.22 ( ) 1.38 ( ) 1.17 ( ) 1.20 ( ) 1.28 ( ) 1.28 ( ) 1.16 ( ) 1.23 ( ) 1.21 ( )
20 Hospitalized/fatal HF in Subgroups - Lisinopril / Chlorthalidone Relative Risks from Baseline to 1 Year of Follow-up 20 Relative Risk (95% CI) Favors Lisinopril Favors Chlorthalidone Total Age < 65 Age 65 Non-Black Black Men Women Diabetic Non-Diabetic 2.08 ( ) 2.53 ( ) 1.98 ( ) 2.04 ( ) 2.15 ( ) 1.80 ( ) 2.40 ( ) 1.99 ( ) 2.16 ( )
21 Hospitalized/fatal HF in Subgroups - Lisinopril / Chlorthalidone Relative Risks After 1 Year of Follow-up 21 Relative Risk (95% CI) Favors Lisinopril Favors Chlorthalidone Total Age < 65 Age 65 Non-Black Black Men Women Diabetic Non-Diabetic 0.96 ( ) 0.95 ( ) 0.97 ( ) 0.90 ( ) 1.10 ( ) 1.02 ( ) 0.89 ( ) 1.01 ( ) 0.93 ( )
22 HF Development and Relation to Other Outcomes 22 HF development associated with: 6.6-fold increase in death rate 11.7-fold increase in CV death rate Previous MI 5.7-fold increased HF risk Of participants with hospitalized HF: 72% hospitalized once 23.3% hospitalized 2-3 times 4.7% hospitalized 4+ times
23 Why are hazard ratios not constant throughout? Hypotheses? 23 Withdrawal from BP meds used prior to enrollment Time course for effect of first-step (primary) drug Diuretic immediate? ACEI delayed? Addition of step-up meds (esp. anti-hf meds) Differences in BP
24 Prior Use of Antihypertensive Agents 24 Prior medication use associated with HF risk, especially during first year RR 1.42 ( ) Relative benefits of chlorthalidone consistent with or without prior antihypertensive medication use
25 Specific Prior Antihypertensive Agents 25 Data not collected within ALLHAT Available for 1115 / 1773 HF cases CCB s 47% ACEI 37% Diuretics 39% Case-only analysis No evidence for any statistically significant interaction between prior drug type (e.g., diuretic) and treatment effect for HF, overall or during the first year
26 Immediate vs Delayed Effects 26 Do diuretics have a more immediate effect on HF prevention than ACEI or ARB? Effect of diuretics begins at trial onset Several ACEI vs placebo studies suggest that ACEI effect is not immediate VALUE trial valsartan vs amlodipine HF similar in first 2 years, strong trend afterward favoring valsartan
27 27 ALLHAT Use of Step-up BP Meds Addition of Step 2 and Step 3 meds could have contributed to lessening or cessation of divergence of HF curves after 1 year.
28 Open-Label ACEI and Atenolol Use 28 Percent Year 3 Years 5 Years Chlor - AC Amlod - AC Lisin - AC Chlor - AT Amlod - AT Lisin - AT
29 30.0 Open-Label Diuretic and CCB Use Percent Year 3 Years 5 Years Chlor - D Amlod - D Lisin - D Chlor - CCB Amlod - CCB Lisin - CCB
30 Percent Diuretic, ACEI, or Atenol Use 1 Year 3 Years 30 Chlor Amlod Lisin
31 BP Results by Treatment Group 31 Chlorthalidone Amlodipine Lisinopril mm Hg BP 140 mm Hg BP Years Years Compared to chlorthalidone: SBP significantly higher in the amlodipine group (~1 mm Hg) and the lisinopril group (~2 mm Hg). Compared to chlorthalidone: DBP significantly lower in the amlodipine group (~1 mm Hg).
32 32 ALLHAT BP Differences Adjustment for follow-up SBP as timedependent covariates in a Cox regression model only slightly modified the relative risks Amlodipine/chlorthalidone first year, after 1 year Lisinopril/chlorthalidone first year, after 1 year
33 33 ALLHAT All-Cause Mortality Cumulative Event Rate Chlorthalidone Amlodipine Lisinopril Years from Hospitalized HF to Death
34 34 ALLHAT Post-HF Mortality Mortality rates after hospitalized HF high relative to those seen in ALLHAT overall 25% vs 5% at 2.5 years, respectively No significant treatment group differences for post-hf mortality The reason that the treatment difference for hospitalized HF did not translate into an effect on total mortality is that only 5.6% of all deaths were attributed to HF.
35 Heart Failure and Total Mortality 35 Lisinopril-chlorthalidone absolute difference in hospitalized HF over 6 years was 0.4%. The excess of cases in the lisinopril group = 36 patients. Case-fatality rate over average follow-up of 2.5 years = 25%. Thus, 9 excess cases of fatal HF would be expected in the lisinopril group. This is fewer than 1% of all deaths in the lisinopril group (n=1314). Similar calculations for the amlodipine group: 154 excess cases of hospitalized HF Estimated number of fatal HF cases was 39, 3% of the amlodipine deaths (n=1256).
36 36 ALLHAT Effect on Total Mortality HF differences in the trial would not have affected differences in total mortality Also noted in the BPLTTC analyses Absolute HF risk low Increase in RR outweighed by even small reduction in higher absolute risks for stroke and CHD Differences in # of HF events during trial result in only very small differences in # of deaths ALLHAT post-trial mortality surveillance to examine this further
37 37 ALLHAT Conclusions 1 Chlorthalidone superior to amlodipine in both time periods Chlorthalidone superior to lisinopril during the first year True for subgroups age, race, sex, diabetes history Other factors could not individually account for all of the observed treatment differences Prior antihypertensive meds Other open-label BP meds Follow-up BP differences
38 38 ALLHAT Conclusions 2 Developing HF is associated with a high mortality rate (~50% at 5 years) It may take time for HF differences to translate into detectable mortality differences between treatments Diuretics are clearly preferred over CCBs overall and over ACE inhibitors, at least in the short term, in preventing HF.
39 Extra Slides 39
40 40 ALLHAT Placebo-Controlled Trials Most placebo-controlled trial have used diuretics and/or β-blockers as active regimens Diuretics & ACEI shown to prevent HF in patients with hypertension SHEP, HOPE CCB vs placebo trials less conclusive Syst-Eur Meta-analyses active therapy of hypertension can prevent >40% of HF events Psaty, Smith, Siscovick, et al.
41 41 ALLHAT Active-Controlled Trials VALUE STOP Hypertension-2 ANBP2 INVEST CONVINCE CCB or diuretic/β-blocker BP reduced similarly, HF 30% more with CCB
42 42 ALLHAT BPLTTC Meta-Analyses CCB-based therapies NS 20% increase in HF incidence compared with placebo 33% higher risk of HF compared with diuretic/β-blocker ACEI-based therapies 18% fewer HF events than with CCB or placebo 7% NS higher risk than with diuretic/ β-blocker CCBs less effective in preventing HF than other regimens ACEI no more effective in preventing HF than diuretic/ β-blocker
43 Randomized Design of ALLHAT 43 High-risk hypertensive patients 55 years Consent / Randomize (42,418) Amlodipine Chlorthalidone Doxazosin Lisinopril Eligible for lipidlowering Not eligible for lipid-lowering Consent / Randomize (10,355) Pravastatin Usual care Follow for CHD and other outcomes until death or end of study (up to 8 yr).
44 Event Reduction in SHEP, Syst-Eur Eur, and HOPE 44 0 Stroke CHD CHF CVD Death Risk Reduction, % SHEP Syst-Eur HOPE SHEP: Systolic Hypertension in the Elderly, n=4,736; chlorthalidone Syst-Eur Eur: : Systolic Hypertension in Europe, n=4,695; nitrendipine HOPE: Heart Outcomes Prevention Evaluation Study, n=9,297; ramipril
Randomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationDrug-Induced Diabetes May Not Be Harmful But Should Be Prevented. Jeffrey A. Cutler, MD, MPH
Drug-Induced Diabetes May Not Be Harmful But Should Be Prevented Jeffrey A. Cutler, MD, MPH Overview Focus on thiazide-like diuretics (not BB) Diuretic-induced versus diureticassociated diabetes Role of
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationOutcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA. 2005;293:
ORIGINAL CONTRIBUTION Outcomes in Hypertensive and Patients Treated With, Amlodipine, and Lisinopril Jackson T. Wright, Jr, MD, PhD J. Kay Dunn, PhD Jeffrey A. Cutler, MD Barry R. Davis, MD, PhD William
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationTREATMENT AND COMPLICAtions
ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationJackson T. Wright, Jr. MD, PhD
DIFFERENTIAL EFFECTS OF BLOOD PRESSURE MEDICATIONS IN BLACK PATIENTS Jackson T. Wright, Jr. MD, PhD Professor of Medicine Program Director, WT Dahms MD Clinical Research Unit Clinical and Translational
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationSponsored by the National Heart, Lung, and Blood Institute (NHLBI)
1 U.S. Department of Health and Human Services The Hypertension, Detection, and Follow-up Program (HDFP) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) National
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationCalcium Channel Blockers in Management of Hypertension. Yong-Jin Kim, MD Seoul National University Hospital
Calcium Channel Blockers in Management of Hypertension Yong-Jin Kim, MD Seoul National University Hospital Contents Clinical significance of hypertension CCB: Brief introduction Evidences of CCB s in HT
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More information2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines
Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationObjective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel
Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline
More informationManagement of The Patients with Hypertension and High Risk Cardiovascular Disease
Management of The Patients with Hypertension and High Risk Cardiovascular Disease Songsak Kiatchoosakun, MD. Cardiology, Medicine Khon Kaen University CVD and Hypertension: Worldwide Morbidity and Mortality
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationThe Antihypertensive and Lipid-Lowering treatment to. Article
Article Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationApplying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients
Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients Joe Anderson, PharmD, PhC, BCPS James Nawarskas, PharmD, PhC, BCPS Gretchen Ray, PharmD, PhC, BCACP University of
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationHypertension Controversies: SPRINTing to New Goals
Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland
More informationDiagnosis and treatment of hypertension. Kari Nelson, MD MSHS Division of General Internal Medicine VA Puget Sound, University of Washington
Diagnosis and treatment of hypertension Kari Nelson, MD MSHS Division of General Internal Medicine VA Puget Sound, University of Washington Outline Epidemiology Diagnosis Evaluation of individuals with
More informationSBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006
Management of Hypertension in Patients with CAD M. Mohsen Ibrahim, MD Cardiology Department- Cairo University 1. What is the optimal BP in patients with hypertension and CAD? 2. What is the minimum safe
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationThe Antihypertensive and Lipid-Lowering Treatment to
Scientific Contributions Diuretic Versus -Blocker as First-Step Antihypertensive Therapy Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ALLHAT
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDisclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012
How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D.,
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationFirenze 22 settembre 2007
Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non
More information